Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$41.80 USD

41.80
478,250

+0.02 (0.05%)

Updated Jul 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research

A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.

Here's Why You Should Buy Wright Medical (WMGI) Stock Now

by Zacks Equity Research

A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.

Here's Why You Should Invest in McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.

QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark

by Zacks Equity Research

QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.

Here's Why You Should Hold Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.

IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View

by Zacks Equity Research

IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.

Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet

by Zacks Equity Research

Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.

ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum

by Zacks Equity Research

ABIOMED's (ABMD) flagship Impella sees a solid Q3; fiscal 2019 outlook raised.

Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid

by Zacks Equity Research

Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.

AmerisourceBergen (ABC) Beats on Q1 Earnings, Trims EPS View

by Zacks Equity Research

AmerisourceBergen (ABC) registers solid growth at the Pharmaceutical Distribution segment and the World Courier business in first-quarter fiscal 2019.

Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4

by Zacks Equity Research

Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.

SurModics (SRDX) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 1300.00% and 17.68%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio

by Zacks Equity Research

The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.

Nabaparna Bhattacharya headshot

Medical Products Industry Gathering Steam: 3 Stocks to Buy

by Nabaparna Bhattacharya

The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.

Surmodics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Surmodics, Inc. (SRDX) has been struggling lately, but the selling pressure may be coming to an end soon.

Here's Why You Should Invest in Veeva Systems (VEEV) Now

by Zacks Equity Research

Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.

Hill-Rom-Microsoft Tie-Up to Widen Digital Solutions Suite

by Zacks Equity Research

Hill-Rom (HRC) progresses with efforts to gain traction in the digital health space.

Integra (IART) Rises 5% on Robust Preliminary Q4 Results

by Zacks Equity Research

Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.

Boston Scientific Gains on Impressive Preliminary Q4 Results

by Zacks Equity Research

Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.

ResMed Announces Complete Mobi Launch in US Markets for COPD

by Zacks Equity Research

ResMed (RMD) progresses with efforts to boost Respiratory Care suite.

QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales

by Zacks Equity Research

QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.

Hologic Stock Rides on Impressive Preliminary Q1 Result

by Zacks Equity Research

Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.

ResMed Closes Propeller Health Buyout, Boosts COPD Suite

by Zacks Equity Research

ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.